Novavax, Inc.NVAXNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +283.03% | -69.69% | +610.30% | -42.42% | -16.64% |
| Gross Profit Growth | +0.00% | -63.75% | +1348.61% | -39.06% | +104.87% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | -32.98% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | -34.37% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | -34.41% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | -40.54% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | -39.39% | +0.00% |
| Weighted Average Shares Growth | +54.74% | +29.56% | +15.10% | +9.19% | +1.44% |
| Weighted Average Shares Diluted Growth | +54.74% | +29.56% | +26.95% | +6.85% | +1.44% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | -140.56% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | -141.04% | +0.00% |
| Receivables Growth | -23.21% | -63.57% | +108.19% | +605.17% | -64.01% |
| Inventory Growth | -87.59% | -79.02% | -34.95% | +11.64% | +56.41% |
| Asset Growth | +3.34% | -13.19% | -4.47% | -26.51% | -31.10% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +5.04% | +0.58% | -0.29% | -2.04% | +7.64% |
| R&D Expense Growth | -17.95% | -36.62% | -4.04% | -27.41% | +12.75% |
| SG&A Expenses Growth | -34.16% | -49.53% | -41.57% | -59.91% | -55.26% |